Cell Immunotherapies for Solid Tumors Summit

Memo

Turning cold tumors hot by unravelling the biology of the tumor microenvironment is critical to the success of cell immunotherapies. Showcasing the advances in the pursuit of clean targets, arming against the tumor microenvironment, and advancing cell trafficking strategies, the Cell Immunotherapies for Solid Tumors Summit is your must-attend meeting to advance your clinical pipeline to success. Returning for the 2nd year due to popular demand, this industry-focused meeting will provide your team with cutting-edge advances across CAR-T, TCR, NK and macrophage cell therapies, to enhance your understanding of how these cells interact in the tumor microenvironment and their potential for combination treatments. As the only summit to solely address the challenges specific to solid tumors, join this comprehensive forum to learn novel gene engineering strategies to improve killing, targeting approaches to overcome off-tumor toxicity and safety risks, combination with radiotherapy and checkpoint inhibitors to improve potency, and review clinical trial results to understand how these therapies modulate the tumor microenvironment in patients. Join over 100+ drug developers this November to network, collaborate and deliver on the potential of cell therapies to provide hope to the masses of patients without a cure. https://solid-tumors-summit.com/ 16-18 November, 20219.30am-4:30pm EST | 6.30am-1:30pm PST Contact:This email address is being protected from spambots. You need JavaScript enabled to view it.   URLs:Brochure: https://go.evvnt.com/817228-0?pid=5569Tickets: https://go.evvnt.com/817228-1?pid=5569   Prices:Drug Developers (Earlybird rates, focus day and workshops available): USD 2099.0,Academic (Earlybird rates and workshops available): USD 1899.0,Service Providers (Earlybird rates and workshops available): USD 2599.0   Speakers: Debora Barton, CMO, Carisma Therapeutics, Saul Priceman, Assistant Professor, City of Hope, Aiman Shalabi, VP, Medicines Development Leader, Cell and Gene Therapies, GSK, John Maher, CSO, Leucid Bio and Senior Lecturer in Immunology, Kings College London, Tanja Obradovic, Senior Scientific Director, Cell Therapy/Redirected Immunity, Takeda, Paul Lammers, President and CEO, Triumvira Immunologics   Date and Time: On Tuesday November 16, 2021 at 9:30 am (ends Thursday November 18, 2021 at 4:30 pm)